BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 90 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q2 2024. The put-call ratio across all filers is 0.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $63,926 | +4417.7% | 13,718 | +4816.8% | 0.00% | – |
Q1 2024 | $1,415 | +83.8% | 279 | +1.8% | 0.00% | – |
Q4 2023 | $770 | -25.5% | 274 | -23.9% | 0.00% | – |
Q3 2023 | $1,033 | -17.2% | 360 | +45.7% | 0.00% | – |
Q2 2023 | $1,247 | +3.0% | 247 | -61.5% | 0.00% | – |
Q1 2023 | $1,211 | +181.6% | 641 | +168.2% | 0.00% | – |
Q4 2022 | $430 | -57.0% | 239 | -67.5% | 0.00% | – |
Q3 2022 | $1,000 | 0.0% | 735 | -2.1% | 0.00% | – |
Q2 2022 | $1,000 | -83.3% | 751 | -61.1% | 0.00% | – |
Q1 2022 | $6,000 | -88.7% | 1,930 | -80.7% | 0.00% | – |
Q4 2021 | $53,000 | -53.9% | 10,005 | -26.8% | 0.00% | – |
Q3 2021 | $115,000 | -29.4% | 13,668 | +2.2% | 0.00% | – |
Q2 2021 | $163,000 | -99.0% | 13,379 | -98.0% | 0.00% | -100.0% |
Q1 2021 | $16,250,000 | -23.6% | 669,854 | +0.9% | 0.00% | -20.0% |
Q4 2020 | $21,270,000 | +52.2% | 663,633 | +43.5% | 0.01% | +25.0% |
Q3 2020 | $13,978,000 | +16.5% | 462,387 | +62.5% | 0.00% | +33.3% |
Q2 2020 | $11,996,000 | +2542.3% | 284,532 | +1463.7% | 0.00% | – |
Q1 2020 | $454,000 | – | 18,196 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Boxer Capital, LLC | 2,014,858 | $5,581,000 | 0.29% |
NEA Management Company, LLC | 3,449,845 | $9,556,000 | 0.28% |
Hawkeye Capital Management, LLC | 243,009 | $673,000 | 0.26% |
DAFNA Capital Management LLC | 313,600 | $869,000 | 0.23% |
Artal Group S.A. | 1,646,517 | $4,561,000 | 0.19% |
MPM BioImpact LLC | 239,888 | $664,000 | 0.18% |
RA Capital Management | 2,589,904 | $7,174,000 | 0.16% |
Bellevue Group AG | 3,293,000 | $9,122,000 | 0.11% |
Ikarian Capital, LLC | 159,390 | $441,000 | 0.06% |
PDT Partners, LLC | 66,168 | $183,000 | 0.02% |